Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
Financial Results:
Wockhardt Ltd reported Revenues for Q3FY24 of ₹701.00 Crores up from ₹699.00 Crore year on year, a rise of 0.29%.
Total Expenses for Q3FY24 of ₹796.00 Crores down from ₹803.00 Crores year on year, a fall of 0.87%.
Consolidated Net Profit of -₹86.00 Crores from -₹102.00 Crores in the same quarter of the previous year.
The Earnings per Share is -₹5.76, from -₹6.66 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.